推荐产品
等級
pharmaceutical primary standard
API 家族
prednisone
製造商/商標名
USP
mp
236-238 °C (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1
InChI
1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
InChI 密鑰
XOFYZVNMUHMLCC-ZPOLXVRWSA-N
基因資訊
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Prednisone USP reference standard for specified quality tests and assay use.
Also used to prepare standard, standard stock and internal standard solutions for the assay and performance tests according to the given below monographs of United States Pharmacopeia (USP):
Also used to prepare standard, standard stock and internal standard solutions for the assay and performance tests according to the given below monographs of United States Pharmacopeia (USP):
- Prednisone
- Prednisone Tablets
- Prednisone Oral Solution
- Hydrocortisone Tablets
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
STOT RE 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
其他客户在看
Prednisone Oral Solution
United States Pharmacopeia, 30(1), 3671-3671 (2020)
Prednisone Tablets
United States Pharmacopeia, 45(3), 3672-3672 (2020)
Prednisone
United States Pharmacopeia, 42(2), 3670-3670 (2020)
Hydrocortisone Tablets
United States Pharmacopeia, 44(6), 2234-2234 (2020)
European journal of cancer (Oxford, England : 1990), 41(4), 502-507 (2005-03-02)
Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门